Irinotecán Qilu

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecán Qilu, is a topoisomerase I inhibitor presented as an injection solution for intravenous use. It treats metastatic colorectal cancer and is used as adjuvant therapy for colon cancer in adult patients.

GNH USA supplies Irinotecán Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecán Qilu is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

Metastatic colorectal cancer: improves overall survival and disease control in patients with advanced disease. Adjuvant treatment of colon cancer: reduces the risk of recurrence after surgical resection. Combination therapy for advanced colorectal cancer: enhances efficacy when used with other chemotherapeutic agents.

Irinotecán Qilu may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Diarrhea, which can be severe - Neutropenia (low white blood cell count) - Fatigue and weakness - Alopecia (hair loss) - Mild abdominal pain

Serious or Rare Side Effects: - Febrile neutropenia (infection with fever) - Severe colitis or intestinal perforation - Hepatic toxicity with elevated liver enzymes - Allergic reactions including anaphylaxis - Pulmonary toxicity such as interstitial pneumonitis - Severe electrolyte disturbances

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular complete blood count to detect neutropenia. Assess liver function: evaluate hepatic enzymes prior to and during treatment. Evaluate bowel status: avoid use in patients with recent bowel obstruction or severe diarrhea. Use caution in renal impairment: adjust monitoring for patients with reduced kidney function. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecán Qilu can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase toxicity. - UGT1A1 inhibitors (e.g., atazanavir) – can raise SN‑38 levels. - Concurrent myelosuppressive agents – heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) – may reduce drug exposure. - Anticoagulants such as warfarin – monitor INR for increased bleeding risk. - Other antineoplastic agents – adjust dosing and monitor overlapping toxicities.